SINOPHARM (01099.HK): unit defaults on RMB 28.76 million loan
- The overdue loan is a one-year working capital facility from SPD Bank's Kunming branch at a 3% rate, with principal and interest unpaid from 16 October 2026.
- Sinopharm has not guaranteed the debt and an extension is under discussion; the unit's borrowings mostly fall due within a year and it is small against group revenue and assets.
NewTimeSpace News: On 21 October 2026, Sinopharm Group Co. Ltd. (stock code: 01099) published an overseas regulatory announcement under Listing Rule 13.10B, reproducing the same-day filing on the Shanghai Stock Exchange and other platforms on a subsidiary's failure to repay due debt, for bond 241026.SH (24 Sinopharm 01).
Guokong Dongchang, a consolidated unit, missed principal and interest on a RMB 28.76 million working capital loan from SPD Bank's Kunming branch due 16 October 2026 after its accounts were frozen amid litigation; an extension is under discussion. Sinopharm has not guaranteed the debt. The unit's external interest-bearing debt totals RMB 59 million, mostly bank borrowings due within a year, with overdue debt of RMB 29 million equal to 49%. Sinopharm said the unit is small against group revenue and assets and the matter is not expected to materially affect its solvency or payments on the bond.
